At a glance

At a glance

Cambium Bio Limited (ASX:CMB) is a Sydney-based clinical-stage regenerative medicine company focusing on the development of innovative biologics for ophthalmology and tissue regeneration applications.

Cambium Bio Limited (ASX:CMB) is a Sydney-based clinical-stage regenerative medicine company focusing on the development of innovative biologics for ophthalmology and tissue regeneration applications.

Cambium Bio Limited (ASX:CMB) is a Sydney-based clinical-stage regenerative medicine company focusing on the development of innovative biologics for ophthalmology and tissue regeneration applications.

The Company's proprietary technology, based on human platelet lysate, is being leveraged to create a pipeline of novel therapeutics with a primary focus on ophthalmology.

The Company's proprietary technology, based on human platelet lysate, is being leveraged to create a pipeline of novel therapeutics with a primary focus on ophthalmology.

The Company's proprietary technology, based on human platelet lysate, is being leveraged to create a pipeline of novel therapeutics with a primary focus on ophthalmology.

Cambium Bio's lead product candidate, Elate Ocular®, is being developed to address significant unmet medical needs in the treatment of dry eye disease.

Cambium Bio's lead product candidate, Elate Ocular®, is being developed to address significant unmet medical needs in the treatment of dry eye disease.

Cambium Bio's lead product candidate, Elate Ocular®, is being developed to address significant unmet medical needs in the treatment of dry eye disease.

In addition, the Company's stem cell platform, Progenza™, is being applied to the development of therapies for knee osteoarthritis and other tissue regeneration indications.

In addition, the Company's stem cell platform, Progenza™, is being applied to the development of therapies for knee osteoarthritis and other tissue regeneration indications.

In addition, the Company's stem cell platform, Progenza™, is being applied to the development of therapies for knee osteoarthritis and other tissue regeneration indications.

Cambium Bio is committed to advancing its pipeline through clinical development and commercialization, with the goal of providing transformative treatments to improve patient outcomes.

Cambium Bio is committed to advancing its pipeline through clinical development and commercialization, with the goal of providing transformative treatments to improve patient outcomes.

Cambium Bio is committed to advancing its pipeline through clinical development and commercialization, with the goal of providing transformative treatments to improve patient outcomes.

Board of Directors & Management

Board of Directors & Management

Karolis Rosickas, MS, MBA

Chief Executive Officer

Karolis Rosickas, MS, MBA

Chief Executive Officer

Karolis Rosickas, MS, MBA

Chief Executive Officer

Dr Neera Jagirdar, MD, MPH

Vice President of Clinical and Regulatory Affairs

Dr Neera Jagirdar, MD, MPH

Vice President of Clinical and Regulatory Affairs

Dr Neera Jagirdar, MD, MPH

Vice President of Clinical and Regulatory Affairs

Dr Edmund K. Waller, MD, PhD

Executive Director

Dr Edmund K. Waller, MD, PhD

Executive Director

Dr Edmund K. Waller, MD, PhD

Executive Director

Dr Sebastian Tseng, DDS, MBA

Non-Executive Director

Dr Sebastian Tseng, DDS, MBA

Non-Executive Director

Dr Sebastian Tseng, DDS, MBA

Non-Executive Director

Terence A. Walts, MBA

Executive Director

Terence A. Walts, MBA

Executive Director

Terence A. Walts, MBA

Executive Director

Barry Sechos

Non-Executive Chairman

Barry Sechos

Non-Executive Chairman

Barry Sechos

Non-Executive Chairman

Advisory Board

Advisory Board

Doyle Stulting, MD, PhD

Ophthalmology medical monitor

Doyle Stulting, MD, PhD

Ophthalmology medical monitor

Doyle Stulting, MD, PhD

Ophthalmology medical monitor

Barbara Fant, PharmD

Ophthalmology Regulatory Consultant

Barbara Fant, PharmD

Ophthalmology Regulatory Consultant

Barbara Fant, PharmD

Ophthalmology Regulatory Consultant

Gary R. Stevens, PhD

Clinical statistics consultant

Gary R. Stevens, PhD

Clinical statistics consultant

Gary R. Stevens, PhD

Clinical statistics consultant

Corporate Governance

Corporate governance policies and charters. Cambium Bio and its Board are committed to upholding the highest standards of corporate governance in line with the ASX Corporate Governance Principles and Recommendations (3rd edition).

Process for Evaluating Board and Executive Performance

Process for Evaluating Board and Executive Performance

Apr 8, 2023

Apr 8, 2023

Whistleblower Policy

Whistleblower Policy

Apr 8, 2023

Apr 8, 2023

Securities Trading Policy

Securities Trading Policy

Apr 8, 2023

Apr 8, 2023

Shareholder Communication Policy

Shareholder Communication Policy

Apr 8, 2023

Apr 8, 2023

Continuous Disclosure Policy

Continuous Disclosure Policy

Apr 8, 2023

Apr 8, 2023

Audit and Risk Committee Charter

Audit and Risk Committee Charter

Apr 8, 2023

Apr 8, 2023

Anti-Bribery and Corruption Policy

Anti-Bribery and Corruption Policy

Apr 8, 2023

Apr 8, 2023

Code of Conduct

Code of Conduct

Apr 8, 2023

Apr 8, 2023

Statement of Values

Statement of Values

Apr 8, 2023

Apr 8, 2023

Board Skills Matrix

Board Skills Matrix

Apr 8, 2023

Apr 8, 2023

Remuneration and Nominations Committee Charter

Remuneration and Nominations Committee Charter

Apr 8, 2023

Apr 8, 2023

Diversity Policy

Diversity Policy

Apr 8, 2023

Apr 8, 2023

Board Charter

Board Charter

Apr 8, 2023

Apr 8, 2023

Corporate Governance Statement

Corporate Governance Statement

Aug 30, 2024

Aug 30, 2024

Careers

Careers

Join a world-class team that is passionate about developing transformational regenerative medicines to treat serious diseases.

Join a world-class team that is passionate about developing transformational regenerative medicines to treat serious diseases.

Corporate Headquarters

Cambium Bio Limited

Cambium Bio Limited

Address

16 Goodhope Street

Paddington, NSW 2021

Australia